3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
94
Glioma
32
Brain Neoplasms
29
Melanoma
21
Neoplasms
17
Astrocytoma
17
Sarcoma, Ewing
7
Ovarian Neoplasms
7
Gliosarcoma
7
Carcinoma, Non-Small-Cell Lung
7
Neuroblastoma
6
Neoplasm Metastasis
6
Medulloblastoma
6
Breast Neoplasms
6
Sarcoma
5
Recurrence
5
Diffuse Intrinsic Pontine Glioma
5
Small Cell Lung Carcinoma
4
Rhabdomyosarcoma
4
Oligodendroglioma
4
Spinal Cord Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Central Nervous System Neoplasms
3
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Neuroendocrine Tumors
2
Lymphoma, Follicular
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
Azacitidine
66
venetoclax
21
Decitabine
16
Cytarabine
12
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
7
fludarabine
6
pevonedistat
5
mocetinostat
5
ON 01910
5
Busulfan
5
treosulfan
4
sabatolimab
4
ruxolitinib
4
cedazuridine
4
cc-486
4
Mycophenolic Acid
4
Lenalidomide
4
Injections
4
plerixafor
3
luspatercept
3
imetelstat
3
glasdegib
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Methotrexate
3
GRN163L peptide
3
Clofarabine
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myelodysplastic Syndromes
×
Temozolomide
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts